Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 30 (1), 59-78

17α-alkynyl 3α, 17β-androstanediol Non-Clinical and Clinical Pharmacology, Pharmacokinetics and Metabolism

Affiliations
Clinical Trial

17α-alkynyl 3α, 17β-androstanediol Non-Clinical and Clinical Pharmacology, Pharmacokinetics and Metabolism

Clarence Ahlem et al. Invest New Drugs.

Abstract

17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. In preparation for clinical studies, nuclear hormone receptor and P450 interactions for HE3235 and major metabolites were characterized in vitro, and pharmacokinetics and metabolite profiles were studied in rodents, dogs, and monkeys. Four-week safety studies conducted in rats and dogs indicated a substantial margin of safety for clinical use, and no evidence of electrocardiographic or neurological effects, although anorexia, thrombocytopenia, and hypokalemia were identified as potentially dose-limiting toxicities at superpharmacological exposures. Pharmacokinetics and drug metabolism have been studied in prostate cancer patients.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

References

    1. Eur J Pharmacol. 1974 Jun;27(1):1-4 - PubMed
    1. J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):57-63 - PubMed
    1. Mutat Res. 1975 Feb;31(1):9-15 - PubMed
    1. J Pharmacol Exp Ther. 2010 Apr;333(1):70-80 - PubMed
    1. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9 - PubMed

MeSH terms

LinkOut - more resources

Feedback